StarTric

We are thrilled to announce that StarTric has been invited to present its TriClover technology, for transcatheter repair of the tricuspid valve, at the prestigious Shark Tank Innovation competition, during the CRF TCT event that will go live in just a few days in Washington D.C. StarTric presentation, A Novel Transcatheter Technique to Repair the Tricuspid Valve, will be delivered on Sunday the 27th by our DANIELE ZANOTTI. StarTric is one of the six only finalists, selected among the most promising new technologies of the whole structural heart landscape. This invitation to the #TCT2024 Shark Tank, that adds to the others to present TriClover at two different scientific sessions of next TCT, confirms a deep interest and curiosity among key-opinion-leaders and innovation experts in interventional cardiology. We are more than proud of this recognition and totally committed to make of StarTric's TriClover a new therapeutic reality. Stay tuned and looking forward to see you in Washington D.C.! 🦈

Again in Italy! #atricure #aptivamedical Carmen Zampelli Simona Benedetti Stéphane Chomez Inmaculada Pedrero Mena Esteve Vallve Federico Angelini Camilla Ghisolfi Diego Damaso Matteo Masocco

StarTric will attend #TCT2024 in Washington D.C from this October 27th. 🌟 We are very proud for having been invited to present our transcatheter tricuspid repair technology, TriClover, from the prestigious podium of the #TCT2024. - On Monday the 28th we will present the moderated abstract: “TriClover: A Novel Transcatheter Technique to Repair the Tricuspid Valve With High Potential for Effectiveness and Wide Indications to Treat Tricuspid Regurgitation”, during the session of Tricuspid Repair Studies 1, Station 7, in the Innovation & Exhibit Hall. - On Tuesday the 29th, we will present “A Novel Transcatheter Technique to Repair the Tricuspid Valve (StarTric): Technology Description and Experimental Insights”, during the session TCT Innovation 12, Innovations in Transcatheter Tricuspid Valve Repair Technologies. The TCT will be a great opportunity to show our encouraging first in vivo chronic results to the international scientific community of interventional cardiology. Most of our team will be at the #TCT2024, open to exchange there on the future of #tricuspid valve therapies. See you in Washington! ☘

Incredible experience attending the LSI Europe 24 Conference in Lisbon. ✨ A great opportunity for our Eugenio Passanante to present StarTric progresses and vision to make available a truly effective, safe and easy solution to treat millions of patients suffering from #Tricuspid Regurgitation. Many thanks to #LSIEurope224 for such a powerful platform to engage with medtech professionals, investors, and attend insightful panels on latest industry trends. Looking forward to staying in touch. Exciting times ahead! 🚀

StarTric is very proud to announce the appointment of Dr Azeem Latib as member of its Scientific Advisory Board, teaming up with Ottavio Alfieri, Michele De Bonis and Maurizio Taramasso. Azeem brings to our project his stellar reputation as scientist and physician, and his deep expertise in new structural heart technologies.   Azeem’s experience and advice will be of extreme value in steering the clinical validation path of StarTric's Transcatheter Edge-to-Edge Repair (TEER) technology for the tricuspid valve, all the way from strategic design to successful execution in both Europe and the US.   “I'm very excited about the potential of this novel transcatheter tricuspid technology that is based on an established surgical technique and addresses an unmet clinical in patients with severe TR" Azeem said.   Grateful of his words, we warmly welcome Azeem to the StartTric SAB, so to purse with a shared vision the goal of providing a technology to effectively and safely treat Tricuspid Regurgitation, to millions of patients in need. 

☘ We are excited to announce that StarTric has been selected to participate to LSI Europe 2024 in Lisbon this September 16-20th. Our Eugenio Passanante will be presenting our unique transcatheter repair technology and share insights into our recent advancements and plans for the future. Feel free to connect with him during the event. Looking forward to seeing you there!

Maurizio Taramasso joins the Scientific Advisory Board (SAB) of StarTric! We are really proud to announce that Maurizio Taramasso, (HerzZentrum Hirslanden Zurich, Clinic Hirslanden) is now member of our SAB, chaired by Ottavio Alfieri and coordinated by Michel De Bonis. Maurizio brings to the project a wealth of expertise in interventional cardiology, in particular in tricuspid valve therapies. Besides, he can contribute with his deep knowledge of new technologies and of their clinical validation, an energizing team spirit, acute thinking and a bright reputation for independent judgement. “I am really excited to start this journey, having the strong convintion that the StarTric technology will help many patients suffering from severe tricuspid regurgitation to improve theis quality of life, even in challenging valve anatomy ” Maurizio said. Maurizio has already started to participate as investigator to pre-clinical validation sessions of the StarTric technology, in view of assuming a key role during the clinical validation trials, which will shortly follow the current development of the investigational device. Welcome Maurizio to our growing Team!

We are thrilled to announce that StarTric has successfully secured a new seed financing round, fueling the development of our groundbreaking technology for #transcatheter #tricuspid valve repair. This milestone wouldn’t be possible without the unwavering support of our founders and our investors including NLC Health Ventures, Growth Engine, NLC Health Impact Fund, and several Business Angels. #Tricuspid Regurgitation (TR) is a severe cardiac condition that affects millions of patients globally, many of whom still lack effective and accessible therapeutic options. At StarTric, we are dedicated to fill this critical gap and improve the lives of those impacted by TR. A heartfelt thank you to our clinical partners, investors and supporters for believing in our vision. Together, we are revolutionizing cardiac care. Stay tuned for more exciting updates on our journey! ☘ 🚀

It's our pleasure to share our journey with Unicredit Start Lab being selected as one of the 10 finalists of their #LifeSciences program. 🚀 We do believe this will be a new opportunity to accelerate the development of our technology and foster our network. We thank the team of #UnicreditStartLab to believe in our vision!

Congratulations to prof. Alfieri, along with prof. Frederick St Goar, awardee of the Gruntzig Ethica Award, the highest honour in the interventional cardiology community, for their extraordinary contribution to mitral regurgitation treatment. 🎖 For the StarTric team is a great privilege to work on another succesful technique introduced by Prof. Alfieri, in collaboration with Prof De Bonis, on the #tricuspid valve, that is implementing their vision to perform a Clover repair with a transcatheter device. ☘